A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease.

Trial Profile

A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
  • Indications Dementia
  • Focus Adverse reactions
  • Sponsors Stemedica Cell Technologies
  • Most Recent Events

    • 01 Nov 2016 According to a Stemedica Cell Technologies media release, first patient has been enrolled in this study.
    • 10 Jun 2015 New trial record
    • 09 Jun 2015 US FDA has approved the Investigational New Drug (IND) application for this trial, according to a Stemedica Cell Technologies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top